{{Rsnum
|rsid=951439
|Chromosome=1
|position=163063901
|Orientation=plus
|GMAF=0.4362
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 25.9 | 57.1 | 17.0
| HCB | 30.1 | 54.1 | 15.8
| JPT | 33.9 | 48.2 | 17.9
| YRI | 27.4 | 55.5 | 17.1
| ASW | 26.8 | 46.4 | 26.8
| CHB | 30.1 | 54.1 | 15.8
| CHD | 35.8 | 42.2 | 22.0
| GIH | 24.8 | 53.5 | 21.8
| LWK | 21.1 | 52.3 | 26.6
| MEX | 48.3 | 36.2 | 15.5
| MKK | 27.1 | 43.2 | 29.7
| TSI | 25.7 | 49.5 | 24.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs951439
|Name_s=
|Gene_s=RGS4
|Feature=
|Evidence=PubMed ID:16604300; PubMed ID:17588543; PubMed ID:18204343
|Annotation=This variant is associated with differential antipsychotic treatment response in individuals of african descent. Patients with african descent and rs951439 genotype CC responded better to perphenazine treatment compared with ziprasidone or quetiapine treatments. Patient with European descent and rs951439 TT genotype responded better to risperidone than those with CC genotype. However, no association was find between this variant and incidence or age at onset in schizophrenia as well as treatment responses in Finnish patients.
|Drugs=perphenazine; quetiapine; risperidone; ziprasidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA161889385
}}

{{PMID Auto
|PMID=20414142
|Title=Association study between RGS4 and [[bipolar disorder]] in the Chinese Han population
}}
{{PMID Auto
|PMID=19282471
|Title=RGS4 polymorphisms associated with variability of cognitive performance in a family-based [[schizophrenia]] sample
|OA=1
}}

{{PMID|16380905|OA=1
}} Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios.

{{PMID|16905560}} RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity.

{{PMID|17092693}} RGS4 is not a susceptibility gene for schizophrenia in Japanese: association study in a large case-control population.

{{PMID|18262772|OA=1
}} Association of RGS2 and RGS5 variants with schizophrenia symptom severity.

{{PMID|18804346|OA=1
}} Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia.

{{PMID|18834502|OA=1
}} Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level.

{{PMID|19197363|OA=1
}} A genome-wide investigation of SNPs and CNVs in schizophrenia.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs951439
|overall_frequency_n=59
|overall_frequency_d=128
|overall_frequency=0.460938
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=46
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}